• Revenue of INR 993.8 crores in Q4 FY26, growing 0.9% QoQ in constant currency terms
• EBITDA margin improved 130 bps sequentially to 24.6%, driven by 155 bps from currency tailwinds, 65 bps from operational leverage, offset by 90 bps salary hike impact
• Transportation vertical grew 0.2% QoQ with OEM customers now representing 77% of vertical revenue (up from earlier levels)
• Won two strategic Transportation deals: one from new APAC OEM and another from next-generation mobility services company in US
• Media & Communications grew 5.6% QoQ driven by continued deal ramp-ups and won multi-year large deal from world-leading device OEM for video/broadband products
• Opened offshore development center for Japanese medtech leader Terumo in Healthcare vertical, combining design, engineering and digital capabilities
• Healthcare & Life Sciences declined 13.1% QoQ due to delays in anticipated deal awards, though some deals closed in early Q1 FY27
• Utilization rate at 73%, up from sub-70% levels in previous quarters, with headroom to reach 80%+ before aggressive hiring needed

Tata Elxsi delivered Q4 FY26 with revenue of INR 993.8 crores (0.9% QoQ growth in constant currency) and EBITDA margin of 24.6% (130 bps sequential improvement). While Transportation and Media & Communications showed stability with strategic wins, Healthcare & Life Sciences declined 13.1% QoQ due to delayed deal closures. Management guides for high single-digit growth in FY27 (down from earlier double-digit aspirations) citing geopolitical uncertainties, while targeting 27% PBT margin exit by Q4 FY27.

Tata Elxsi reported Q4 FY26 revenues of INR 993.8 crores with 0.9% QoQ growth in constant currency. EBITDA margin stood at 24.6%, improving 130 basis points sequentially through a combination of 155 bps currency tailwinds (INR depreciation against cross-currencies), 65 bps operational leverage improvements (including better utilization, fixed-price contract optimization, and pyramid management), offset by 90 bps impact from January 2025 salary increases. The margin improvement reflects management's sustained focus on operational excellence with utilization reaching 73% versus sub-70% in earlier quarters. By vertical, Transportation grew 0.2% QoQ, Media & Communications grew 5.6% QoQ, while Healthcare & Life Sciences declined 13.1% QoQ. The company has been disciplined on headcount additions, only hiring where specific requirements exist. Management expects to gradually improve margins toward their target band of 27-28% EBITDA, with a specific goal of 27% PBT margin exit rate by Q4 FY27 (not full year average).

Management displayed a cautiously optimistic tone, balancing acknowledgment of near-term challenges with confidence in strategic positioning. CEO Manoj Raghavan emphasized satisfaction with operational execution, highlighting the 130 bps margin improvement and sustained offshore delivery capabilities. The team's confidence was evident in their Gen AI investments, including launch of automotive SDLC platform, partnerships with AI companies, and enterprise-wide adoption initiatives. However, management was notably more conservative than previous quarter, downgrading FY27 growth expectations from double-digit to high single-digit (7-9% range) due to geopolitical uncertainties and elongated deal cycles. The disappointment around Healthcare's 13.1% decline was palpable, with management explaining that deals they were 'very confident' about closing in Q4 have been delayed by 6 months since October. Strategic priorities emphasized include: (1) scaling differentiated design-led and AI-enabled offerings, (2) pivoting toward OEM business (now 77% of Transportation), (3) transitioning to fixed-price project ownerships, and (4) driving sustainable margin improvements. Management stressed that their growth is entirely organic unlike peers relying on inorganic acquisitions, and highlighted their unique strength in offshore delivery and consolidation deals.

Several significant headwinds emerged during the call. The Healthcare & Life Sciences vertical faces substantial uncertainty, declining 13.1% QoQ with anticipated deals delayed by 6+ months, creating visibility concerns. Management acknowledged the industry remains challenged with no clear recovery timeline. Geopolitical uncertainties and ongoing trade wars are causing customers to delay decision-making, with deal cycles elongating across verticals. The Media & Communications vertical remains 'not out of the woods' with continued industry consolidation, M&A activity creating engineering redundancies, and customer focus on cost-takeout rather than innovation. Transportation faces mixed signals with some aggressive pricing from competitors (though management notes this is selective, not widespread irrational behavior). The regulatory nature of Automotive and Healthcare limits Gen AI adoption compared to Media & Communications, potentially constraining productivity gains. Management flagged that R&D services face structural challenges with 10-15% quarterly revenue run-off requiring constant funnel replenishment, unlike locked-in long-term contracts. Currency volatility remains a factor, with 155 bps of Q4 margin improvement coming from favorable currency movements that could reverse. The company's aspiration shift from double-digit to high single-digit growth for FY27 reflects reduced confidence in near-term momentum. New customers typically contribute only 2-2.5% of quarterly revenue, limiting rapid diversification. Tariff and trade policy uncertainties were mentioned as ongoing concerns affecting customer spending appetite.

Revenue Outlook: High single-digit growth for FY27 (previously aspired for double-digit), with all three verticals expected to show growth. Transportation expected to lead growth but may not reach double-digit. Healthcare expected to recover in Q1 FY27 after Q4 being the bottom.

Margin Outlook: Target 27% PBT margin exit rate by Q4 FY27 (not full year). Gradual quarterly improvement expected from current 24.6% EBITDA. Original margin band goal of 27-28% EBITDA being pursued through operational leverage, fixed-price contracts, and Gen AI productivity.

Key Targets:

• 27% PBT margin exit rate by Q4 FY27
• Continue shift toward OEM business in Transportation (currently 77%)
• Scale newly won multi-million dollar deals over next 6-12 months
• Improve utilization from 73% toward 80%+ before aggressive hiring
• Build new verticals: Aerospace & Defense, Battery Energy Storage, Manufacturing

The Q&A session revealed analyst focus on three primary areas: (1) sustainability of margin improvements and path to management's 27-28% target band, (2) Healthcare vertical's decline and recovery timeline after missing Q4 expectations, and (3) growth outlook for FY27 amid geopolitical uncertainties. Analysts pressed on whether Q4 Healthcare was truly the bottom after similar claims in Q3, with management acknowledging disappointment but expressing confidence deals have now closed in Q1. Multiple questions probed the Gen AI impact on pricing dynamics and productivity, with management emphasizing value creation (time-to-market, quality) over pure cost reduction in R&D services, and noting limited adoption in regulated Automotive/Healthcare versus Media verticals. Concerns about elongated deal cycles and customer decision-making delays were prominent, with management citing 6-month delays on Healthcare deals since October. Analysts also focused on the downgrade from double-digit to high single-digit growth guidance, seeking clarification on what changed. Management responses were balanced - acknowledging challenges and reduced visibility while highlighting strategic wins, operational improvements, and differentiated positioning in offshore delivery and consolidation deals. The tone was defensive on Healthcare but more confident on Transportation and Media momentum. Overall, analysts appeared concerned about execution consistency and near-term visibility, while management worked to reassure on structural improvements (margins, OEM shift, Gen AI) that should drive medium-term performance despite short-term volatility.